Navigation Links
Bone marrow stem cells do not improve short-term recovery after heart attack
Date:11/7/2012

HOUSTON (Nov. 7, 2012) Administering stem cells derived from patients' own bone marrow either three or seven days after a heart attack is safe but does not improve heart function six months later, according to a clinical trial supported by the National Institutes of Health (NIH).

The results of the trial, called Transplantation In Myocardial Infarction Evaluation (TIME), mirror a previous related study, LateTIME, which found that such cells (called autologous stem cells) given two to three weeks after a heart attack did not improve heart function. Both TIME and LateTIME were conducted by the Cardiovascular Cell Therapy Research Network (CCTRN), sponsored by the NIH's National Heart, Lung, and Blood Institute.

The findings were presented Nov. 6, 2012, at the American Heart Association 2012 Scientific Sessions in Los Angeles and appeared concurrently in the Journal of the American Medical Association.

"These cells, while safe, were not better than placebo solution in providing benefit," said Lemuel Moy, III, M.D., Ph.D., principal investigator of the CCTRN and professor of biostatistics at The University of Texas School of Public Health, part of The University of Texas Health Science Center at Houston (UTHealth). "While this one cell type showed little promise, there are several new cell types that are available and we will be studying them. Cell therapy can and likely will play a major role in the treatment of cardiovascular disease in the future."

"This study was extremely valuable even though it did not provide a demonstrated health benefit after six months," said Sonia Skarlatos, Ph.D., deputy director of NHLBI's Division of Cardiovascular Sciences and member of the CCTRN. "Heart stem cell therapy research is still in its infancy, and results from early trials have varied greatly due to differences in the numbers of stem cells injected, the delivery methods used, and the compositions of the study populations. Wi
'/>"/>

Contact: Deborah Mann Lake
deborah.m.lake@uth.tmc.edu
713-500-3030
University of Texas Health Science Center at Houston
Source:Eurekalert

Page: 1 2 3

Related biology news :

1. Study results: Adult stem cells from bone marrow
2. Autologous bone marrow-derived mononuclear cell transplants can reduce diabetic amputations
3. Cell therapy using patients own bone marrow may present option for heart disease
4. Bone marrow transplant arrests symptoms in model of Rett syndrome
5. Stem cells could heal equine tendon injuries
6. Novel technique to produce stem cells from peripheral blood
7. Cellular landscaping: Predicting how, and how fast, cells will change
8. Team uses antisense technology that exploits gene splicing mechanism to kill cancer cells
9. The role of stem cells in developing new drugs
10. Duke researchers engineer cartilage from pluripotent stem cells
11. How to make stem cells - nuclear reprogramming moves a step forward
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/14/2015)... April 14, 2015  HYPR Corp. today announced ... ® ) Alliance tm , an industry consortium ... commit to share technology and collaborate to deliver ... interoperable, more secure and private, and easier to ... verification that protects sensitive user information and eliminates ...
(Date:4/13/2015)... April 13, 2015  higi, a leading cloud-based consumer ... more fully engage with their communities around health and ... protected and secure API.  ... most accessible, affordable, and convenient vehicle to receive validated ... The API will allow higi,s trusted ...
(Date:4/8/2015)... N.C. , April 8, 2015  Infinisource, ... solutions and services, and Morpho, a leading supplier ... partnership to produce the market,s most advanced biometrically-enabled ... Infinisource,s iSolved NXG time clock is setting a ... and labor data for the small and mid-size ...
Breaking Biology News(10 mins):HYPR Corp. Joins the FIDO Alliance 2HYPR Corp. Joins the FIDO Alliance 3higi Launches Seamless Access to HIPAA-Compliant Health Outcomes and Activity Data 2higi Launches Seamless Access to HIPAA-Compliant Health Outcomes and Activity Data 3iSolved Time Clock Offers Unmatched Accuracy due to Morpho Biometrics 2iSolved Time Clock Offers Unmatched Accuracy due to Morpho Biometrics 3
... of life, and occurs naturally in soil and ground water ... has been linked to lung, bladder and kidney cancer, and ... in drinking water. Chemically similar to phosphorus, arsenic forms arsenate ... 4 3- ). Arsenate interferes with many phosphate-requiring metabolic ...
... April 8 to 10, 2010, 185 attendees from 25 ... new tools to humanely and effectively manage populations of ... biology and other related scientific disciplines presented the newest ... health drug development. Veterinary leaders joined with animal welfare ...
... CORVALLIS, Ore. Forestry scientists at Oregon State University ... rate and other characteristics of trees can be changed ... is conceptually similar to traditional plant breeding. Cisgenics ... sexually compatible. If governments choose to regulate it similarly ...
Cached Biology News:Arsenic hyperaccumulating ferns: How do they survive? 2Arsenic hyperaccumulating ferns: How do they survive? 3Momentum builds after 4th International Symposium on Pet Contraception 2Momentum builds after 4th International Symposium on Pet Contraception 3Success with 'cisgenics' in forestry offers new tools for biotechnology 2Success with 'cisgenics' in forestry offers new tools for biotechnology 3
(Date:5/4/2015)... 4, 2015 GliaCure, a privately-held biotechnology ... for neurological and neuropsychiatric disorders based on glial ... Alzheimer,s patients in a Phase 1b clinical trial ... developed as a potential disease-modifying treatment. GliaCure,s innovative ... that it both promotes the clearance of amyloid ...
(Date:5/4/2015)... - Fluorinov Pharma (Fluorinov), a FACIT portfolio company, ... Roger J Garceau, to its Board of Directors. ... including corporate development and clinical strategy, his appointment ... expertise as Fluorinov transitions to clinical development.  ... pharmaceutical development experience to Fluorinov and most recently ...
(Date:5/4/2015)... 2015 Genedata, a leading provider ... life science research, today announced the release of ... of its enterprise solution for biologics R&D. This ... efficient discovery and development of novel biotherapeutics. Version ... address protein optimization and developability requirements. Genedata will ...
(Date:5/4/2015)... HONG KONG , May 4, 2015 ... or the "Company"), China,s leading ... cell processing and stem cell storage services, today announced ... Holdings Limited ("Golden Meditech"), a Hong Kong ... the Company, has entered into an agreement (the "Agreement") ...
Breaking Biology Technology:GliaCure Initiates Phase 1b Dosing in Alzheimer's Patients 2Roger J Garceau joins Fluorinov board, adds clinical expertise to bromodomain program and oncology pipeline 2Roger J Garceau joins Fluorinov board, adds clinical expertise to bromodomain program and oncology pipeline 3Genedata Biologics 5.0 – Antibody Engineering and Developability Assessment Advances 2Genedata Biologics 5.0 – Antibody Engineering and Developability Assessment Advances 3Genedata Biologics 5.0 – Antibody Engineering and Developability Assessment Advances 4China Cord Blood Corporation Receives Notice of a Transaction Regarding its 7% Senior Convertible Notes Due 2017 Held by KKR 2China Cord Blood Corporation Receives Notice of a Transaction Regarding its 7% Senior Convertible Notes Due 2017 Held by KKR 3
... -- 3SBio Inc. (NASDAQ: SSRX ) ... company focused on researching, developing, manufacturing and marketing ... its first quarter 2011 unaudited financial results after ... 11, 2011 at 8:00pm (US Eastern ). ...
... that a new market research report is available in ... Global Markets http://www.reportlinker.com/p0488650/Medical-Enzymes-Technologies-and-Global-Markets.html ... growing. The global market for medical enzymes is estimated ... at a compound annual growth rate (CAGR) of 3.9%, ...
... Novavax, Inc. (Nasdaq: NVAX ) will report financial ... 9, 2011, before the U.S. financial markets open.  The announcement ... by Stanley C. Erck, President and Chief Executive Officer, and ... The webcast and conference call will be ...
Cached Biology Technology:3SBio Inc. Schedules Unaudited First Quarter 2011 Results 2Reportlinker Adds Medical Enzymes: Technologies and Global Markets 2Reportlinker Adds Medical Enzymes: Technologies and Global Markets 3Reportlinker Adds Medical Enzymes: Technologies and Global Markets 4Reportlinker Adds Medical Enzymes: Technologies and Global Markets 5Reportlinker Adds Medical Enzymes: Technologies and Global Markets 6Reportlinker Adds Medical Enzymes: Technologies and Global Markets 7Reportlinker Adds Medical Enzymes: Technologies and Global Markets 8Reportlinker Adds Medical Enzymes: Technologies and Global Markets 9Reportlinker Adds Medical Enzymes: Technologies and Global Markets 10Reportlinker Adds Medical Enzymes: Technologies and Global Markets 11Reportlinker Adds Medical Enzymes: Technologies and Global Markets 12Reportlinker Adds Medical Enzymes: Technologies and Global Markets 13
D.R. Harper (1993) • Includes: essential information on taxonomy, culture and safe handling of viruses, immunology, monoclonal antibodies, antivirals and vaccines....
...
Performance, mycoplasma, virus, and endotoxin tested. Collected from calves 14 days old or less...
...
Biology Products: